SALT LAKE CITY, UT / ACCESS Newswire / May 6, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty and one-half cents ($.305) per share of common stock payable on July 3, 2025 to stockholders of record at the close of business on June 16, 2025. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.
Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal long-term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD's website at www.utahmed.com.
Contact: Brian Koopman
(801) 566-1200
| Last Trade: | US$60.74 |
| Daily Change: | 0.40 0.66 |
| Daily Volume: | 9,950 |
| Market Cap: | US$194.980M |
July 24, 2025 November 05, 2024 October 29, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
